Last $11.98 USD
Change Today -0.02 / -0.17%
Volume 12.5K
As of 8:10 PM 09/12/14 All times are local (Market data is delayed by at least 15 minutes).

genocea biosciences inc (GNCA) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/10/14 - $23.99
52 Week Low
02/7/14 - $10.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

genocea biosciences inc (GNCA) Related Businessweek News

No Related Businessweek News Found

genocea biosciences inc (GNCA) Details

Genocea Biosciences, Inc., a clinical stage biotechnology company, discovers and develops novel vaccines to treat infectious diseases. It uses its proprietary discovery platform, AnTigen Lead Acquisition System, to design vaccines that act through T cell immune responses. The company is developing its lead product candidate, GEN-003, a therapeutic vaccine or an immunotherapy that is in Phase I/IIa trial to treat people with herpes simplex virus-2 (HSV-2) infections. It is also developing GEN-004, a vaccine candidate, which is in Phase I trial to prevent infections caused by pneumococcus; GEN-001 that is in pre-clinical stage for treating chlamydia prophylaxis; GEN-002, which is in pre-clinical stage for the treatment of HSV-2 prophylaxis; and GEN-005 that is in research stage for treating malaria prophylaxis. The company was founded in 2006 and is based in Cambridge, Massachusetts.

44 Employees
Last Reported Date: 03/21/14
Founded in 2006

genocea biosciences inc (GNCA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $334.3K
Chief Medical Officer
Total Annual Compensation: $331.5K
Senior Vice President of Research
Total Annual Compensation: $238.3K
Vice President of Biopharmaceutical Developme...
Total Annual Compensation: $257.3K
Compensation as of Fiscal Year 2013.

genocea biosciences inc (GNCA) Key Developments

Genocea Biosciences, Inc. Commences Phase 2a Trial for GEN-004

Genocea Biosciences, Inc. announced the initiation of a Phase 2a trial for GEN-004, the company's universal vaccine candidate against pneumococcus. The trial is designed to evaluate the effect of dosing with GEN-004 on the frequency, magnitude and duration of colonization by pneumococcus in the nasopharynx of healthy adults. The Phase 2a study will enroll approximately 90 healthy adult subjects from one site in the United Kingdom. Subjects will be randomized to placebo or GEN-004. Those subjects receiving GEN-004 will be dosed three times at one month intervals with 100 micrograms per protein and 350 micrograms of alum. All subjects will be challenged with pneumococcus after the third dose of GEN-004 or placebo.

Genocea Biosciences, Inc. Appoints Kenneth Bate as Chairman of Compensation Committee and Member of the Audit Committee

Genocea Biosciences, Inc. announced that Kenneth Bate has joined the company's board of directors. Mr. Bate will also serve as chairman of the company's Compensation committee and a member of the Audit committee. He currently is chairman of the board of Cubist Pharmaceuticals, Inc., and is a director of BioMarin Pharmaceuticals, AVEO Pharmaceuticals and Catabasis Pharmaceuticals.

Genocea Presents Phase 1 Immunology Data for Novel Pneumoccocus Vaccine at ICAAC

Genocea Biosciences, Inc. presented data from a Phase 1 study of GEN-004, an investigational vaccine designed to prevent disease caused by all serotypes of pneumococcus (Streptococcus pneumoniae) The poster (G-291), titled 'Safety and Immunogenicity of a Novel Lipidated Protein Subunit Streptococcus Pneumoniae vaccine,' was presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. Data presented at ICAAC showed the GEN-004 study met safety, tolerability and immunogenicity goals, including increases in the blood of T helper 17 (T(H) 17) cells, a rare cell type that provides immunity at epithelial and mucosal surfaces. By generating a T(H) 17 T cell-mediated immune response, immunization with GEN-004 may prevent or reduce pneumococcus colonization in the nasopharynx, a precursor to infection caused by all serotypes of pneumoccocus. The Phase 1 study was a randomized, double-blind, dose-escalation, placebo-controlled clinical trial that enrolled 90 healthy adult volunteers. The primary objective was to evaluate safety and tolerability of GEN-004, which is comprised of three protein antigens, SP0148, SP2108 and SP1912, when administered with and without aluminum hydroxide as an adjuvant. Subjects were randomized to receive 10, 30 or 100ug of each protein/dose with or without 350ug aluminum hydroxide, or placebo, and received three doses, each four weeks apart. GEN-004 was administered by an intramuscular injection. The study showed that at 85 days after administration, GEN-004 was safe and well tolerated at all doses. The most common side effects were pain, tenderness, muscle aches and fatigue. Most were mild or moderate in intensity. There were no serious adverse events related to the vaccine. As a secondary objective, the study measured peripheral T(H) 17 levels, by means of IL-17 responses, and IgG (serum antibody) immune responses. IgG responses were observed at all doses tested, both in the presence and absence of the adjuvant. IL-17 responses were observed in the 100 ug dose group and were dependent on the presence of aluminum hydroxide. The highest dose from this trial of 100ug will be further evaluated in an upcoming Phase 2a study.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNCA:US $11.98 USD -0.02

GNCA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $3.77 USD +0.05
GenVec Inc $2.35 USD -0.02
Progenics Pharmaceuticals Inc $5.27 USD -0.15
Vical Inc $1.18 USD -0.04
ZIOPHARM Oncology Inc $3.22 USD +0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation GNCA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 855.2x
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 574.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENOCEA BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at